Quick Answer
Kiniksa Pharmaceuticals International, plc reported Total Revenue of $677.56 million for fiscal year 2025.
Kiniksa Pharmaceuticals International, plc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $677.56M +60.1% |
$423.24M +56.6% |
$270.26M +22.7% |
$220.18M +471.2% |
$38.54M | — |
| Revenue (ASC 606) | $677.56M +60.1% |
$423.24M +56.6% |
$270.26M +22.7% |
$220.18M +471.2% |
$38.54M | — |
| Net Income | $59.01M +236.6% |
-$43.19M -406.7% |
$14.08M -92.3% |
$183.36M +216.1% |
-$157.92M +2.1% |
-$161.38M +0.3% |
| Diluted EPS | $0.75 +225.0% |
-$0.60 -400.0% |
$0.20 -92.3% |
$2.60 +213.0% |
-$2.30 +11.9% |
-$2.61 +12.7% |
| Total Assets | $763.63M +31.5% |
$580.55M +10.3% |
$526.32M +14.5% |
$459.67M +97.5% |
$232.80M -33.4% |
$349.46M +37.3% |
| Cash and Equivalents | $165.60M -9.8% |
$183.58M +70.1% |
$107.95M -12.0% |
$122.72M +0.2% |
$122.47M +7.4% |
$114.04M +143.0% |
| Stockholders Equity | $567.61M +29.5% |
$438.44M -0.1% |
$438.84M +10.8% |
$396.15M +114.1% |
$185.04M -40.7% |
$311.94M +38.4% |
| R&D Expense | $96.85M -13.2% |
$111.62M +46.7% |
$76.10M +16.2% |
$65.49M -34.0% |
$99.30M -11.4% |
$112.04M -17.0% |
| Operating Income | $77.22M +269.3% |
-$45.62M -81.0% |
-$25.20M -357.8% |
$9.77M +106.2% |
-$156.64M +0.5% |
-$157.36M +7.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $180.85M | +61.2% | +15.3% |
| Revenue (ASC 606) | September 30, 2025 | $180.85M | +61.2% | +15.3% |
| Net Income | September 30, 2025 | $18.43M | +245.2% | +3.4% |
| Diluted EPS | September 30, 2025 | $0.23 | +227.8% | +0.0% |
| Total Assets | September 30, 2025 | $712.33M | +28.3% | +7.7% |
| Cash and Equivalents | September 30, 2025 | $174.86M | +79.6% | -8.9% |
| Stockholders Equity | September 30, 2025 | $535.38M | +22.5% | +8.2% |
| R&D Expense | September 30, 2025 | $24.17M | -7.3% | +28.9% |
| Operating Income | September 30, 2025 | $24.02M | +348.7% | +19.2% |
- Kiniksa Pharmaceuticals International, plc reported Total Revenue of $677.56 million for fiscal year 2025.
- Kiniksa Pharmaceuticals International, plc showed an increase of +60.1% in Total Revenue compared to the prior fiscal year.
- Kiniksa Pharmaceuticals International, plc reported Revenue (ASC 606) of $677.56 million for fiscal year 2025.
- Kiniksa Pharmaceuticals International, plc showed an increase of +60.1% in Revenue (ASC 606) compared to the prior fiscal year.
- Kiniksa Pharmaceuticals International, plc reported Net Income of $59.01 million for fiscal year 2025.
- Kiniksa Pharmaceuticals International, plc showed an increase of +236.6% in Net Income compared to the prior fiscal year.
- Kiniksa Pharmaceuticals International, plc reported Diluted EPS of $0.75 per share for fiscal year 2025.
- Kiniksa Pharmaceuticals International, plc showed an increase of +225.0% in Diluted EPS compared to the prior fiscal year.
- Kiniksa Pharmaceuticals International, plc reported Total Assets of $763.63 million for fiscal year 2025.
- Kiniksa Pharmaceuticals International, plc showed an increase of +31.5% in Total Assets compared to the prior fiscal year.
- Kiniksa Pharmaceuticals International, plc reported Cash and Equivalents of $165.60 million for fiscal year 2025.
- Kiniksa Pharmaceuticals International, plc showed a decrease of -9.8% in Cash and Equivalents compared to the prior fiscal year.
- Kiniksa Pharmaceuticals International, plc reported Stockholders Equity of $567.61 million for fiscal year 2025.
- Kiniksa Pharmaceuticals International, plc showed an increase of +29.5% in Stockholders Equity compared to the prior fiscal year.
- Kiniksa Pharmaceuticals International, plc reported R&D Expense of $96.85 million for fiscal year 2025.
- Kiniksa Pharmaceuticals International, plc showed a decrease of -13.2% in R&D Expense compared to the prior fiscal year.
- Kiniksa Pharmaceuticals International, plc reported Operating Income of $77.22 million for fiscal year 2025.
- Kiniksa Pharmaceuticals International, plc showed an increase of +269.3% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: